Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope drug tested for Tough-to-Treat mesothelioma

NCT ID NCT06840834

Recruiting now Disease control Sponsor: Intergroupe Francophone de Cancerologie Thoracique Source: ClinicalTrials.gov ↗

Summary

This study is testing a new drug called ivonescimab for people with pleural mesothelioma whose cancer has grown again after receiving standard immunotherapy and chemotherapy. About 38 participants will receive the drug every three weeks for up to two years. The main goal is to see if the treatment can control the cancer for at least 12 weeks.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PLEURAL MESOTHELIOMAS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Besançon - CHU

    RECRUITING

    Besançon, France

  • Bordeaux - CHU

    RECRUITING

    Pessac, France

  • Brest - CHU

    RECRUITING

    Brest, France

  • Caen - CHU

    RECRUITING

    Caen, France

  • Clermont-Ferrand - Centre Jean Perrin

    RECRUITING

    Clermont-Ferrand, France

  • Créteil - CHI

    RECRUITING

    Créteil, France

  • Grenoble - CHU

    RECRUITING

    Grenoble, France

  • Le Mans - CHG

    RECRUITING

    Le Mans, France

  • Lille - CHU

    RECRUITING

    Lille, France

  • Lyon - HCL

    RECRUITING

    Pierre-Bénite, France

  • Marseille - APHM

    RECRUITING

    Marseille, France

  • Metz - Hôpital Robert Schuman

    RECRUITING

    Vantoux, France

  • Montpellier - CHU

    RECRUITING

    Montpellier, France

  • Mulhouse - GHRMSA

    RECRUITING

    Mulhouse, France

  • Nantes - Hôpital Laennec

    RECRUITING

    Nantes, France

  • Paris - Bichat

    RECRUITING

    Paris, France

  • Strasbourg - Nouvel Hôpital Civil

    RECRUITING

    Strasbourg, France

  • Toulon - CHI

    RECRUITING

    Toulon, France

  • Toulouse - CHU

    RECRUITING

    Toulouse, France

  • Tours - CHU

    RECRUITING

    Tours, France

Conditions

Explore the condition pages connected to this study.

PLEURAL MESOTHELIOMAS